
The U.S. Food and Drug Administration (FDA) has placed a clinical hold on SRP-5051 (vesleteplirsen), Sarepta Therapeutics' (NASDAQ:SRPT) lead candidate to treat patients with Duchenne muscular dystrophy.
The regulatory decision follows a serious adverse event of hypomagnesemia in the Part B of MOMENTUM Study 5051-201, investigated SRP-5051 (vesleteplirsen) for Duchenne muscular dystrophy in the Phase 2 clinical trial.